eric
07-30-2004, 08:30 AM
Several novel cytotoxic drugs in development and undergoing phase 2 and 3 trials may soon offer clinicians new treatment options for patients with metastatic breast cancer that is resistant or refractory to standard therapies.
http://www.docguide.com/news/content.nsf/EAC/8525697700573E1885256EE000729C8B?Open&type=
http://www.docguide.com/news/content.nsf/EAC/8525697700573E1885256EE000729C8B?Open&type=